Moderna Suspends Construction of Vaccine Plant in Kenya Due to Low Demand

The biotech firm halts its $500 million project as vaccine orders in Africa cease, reflecting a significant downturn in COVID-19 vaccine demand on the continent.

• Moderna has paused its plans to build a $500 million mRNA vaccine manufacturing facility in Kenya, citing insufficient demand for COVID-19 vaccines in Africa.
• The company has not received any vaccine orders for Africa since 2022, leading to over $1 billion in losses and write-downs.
• Despite the project halt, Moderna remains committed to ensuring equitable vaccine access in Africa through its global manufacturing network.
• The decision aligns with Moderna's broader strategy to resize its COVID-19 vaccine production in response to the reduced global demand.
• Moderna is also focusing on developing vaccines for other diseases prevalent in Africa, such as HIV and malaria, which are still in early stages of development.

3 Articles

Boston Globe Quartz CNBC